Avibactam-based combinations for the treatment of multidrug resistant Gram-negative bacilli infections
Abstract
The approach to multidrug-resistant (MDR) Gram-negative bacilli (GNB) infections has changed following the introduction of avibactam-based β-lactam/β-lactamase inhibitor combinations. Ceftazidime/avibactam has become a cornerstone for the treatment of infections caused by KPC-producing Enterobacterales, whereas the recent availability of aztreonam/avibactam has provided the first targeted option against metallo-β-lactamase (MBL)-producing Enterobacterales. At the same time, the emergence of KPC variants, the increasing dissemination of MBLs and the growing complexity of resistance mechanisms have made both empirical and targeted therapeutic decisions increasingly challenging. This narrative review summarizes the current evidence regarding the microbiological activity, clinical efficacy and optimal place in therapy of avibactam-based combinations. Ceftazidime/avibactam is a cornerstore for the treatment of KPC infections, and significantly modified the outcome of patients with KPC infections during the last decade. Robust observational studies demonstrated its clinical efficacy and safety. It may also represent a carbapenem-sparing option for treating infections due to difficult-to-treat ESBL- and OXA-48-producing Enterobacterales. Moreover, its activity against MDR Pseudomonas aeruginosa makes it an attractive option for empirical therapy in patients with risk factors for this non-fermenting GNB. Aztreonam/avibactam represents the first-line option for the treatment of…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.